Esperion: Grand Slam in Cholesterol Reduction

 Comments Off on Esperion: Grand Slam in Cholesterol Reduction
Sep 072017
 
Esperion: Grand Slam in Cholesterol Reduction

Non-alcoholic steatohepatitis, or NASH, is one of the largest disease opportunities we have ever seen, explains John McCamant, editor of The Medical technology Stock Letter.

Intrexon: Biotech, Biofuels & Fish Farming

 Comments Off on Intrexon: Biotech, Biofuels & Fish Farming
Jul 092017
 
Intrexon: Biotech, Biofuels & Fish Farming

Intrexon (XON) has had a very busy few weeks as the company has delivered a slew of positive news, explains John McCamant, editor of The Medical Technology Stock Letter.

Top Picks 2017: Madrigal

 Comments Off on Top Picks 2017: Madrigal
Jan 242017
 
Top Picks 2017: Madrigal

Non-alcoholic steatohepatitis, or NASH, is one of the largest disease opportunities we have ever seen, explains John McCamant, editor of The Medical technology Stock Letter.

Top Picks 2017: The Medicines Company

 Comments Off on Top Picks 2017: The Medicines Company
Jan 182017
 
Top Picks 2017: The Medicines Company

The next-generation of cholesterol drugs were approved in 2016; these targeted drugs rapidly reduce LDL cholesterol in a wide variety of patients with cardiovascular disease, notes Jay Silverman, editor of the Medical Technology Stock Letter.

Top Picks 2017: Incyte (1-06-2017)

 Comments Off on Top Picks 2017: Incyte (1-06-2017)
Jan 072017
 
Top Picks 2017: Incyte (1-06-2017)

This Top Pick for 2017 may very well have the best and broadest early-stage oncology pipeline with 12 drug development candidates, suggests John McCamant, editor The Medical Technology Stock Letter.

10 biotech companies ripe for a buyout, courtesy of Donald Trump (11-17-16)

 Comments Off on 10 biotech companies ripe for a buyout, courtesy of Donald Trump (11-17-16)
Nov 292016
 
10 biotech companies ripe for a buyout, courtesy of Donald Trump (11-17-16)

November 17, 2016 Opinion : 10 biotech companies ripe for a buyout, courtesy of Donald Trump (11-17-16) The Republican sweep of Washington has generated a ton of enthusiasm for biotech stocks. They’re up 10% to 15% since the elections. As a result, biotech analysts’ phones are ringing off the hook again after a depressingly bleak […]

Incyte: A Promising Pipeline (11-14-2016)

 Comments Off on Incyte: A Promising Pipeline (11-14-2016)
Nov 162016
 
Incyte: A Promising Pipeline (11-14-2016)

John McCamant, editor The Medical Technology Stock Letter, reviews a favored biotech stock Incyte (INCY), noting that the company will have a very strong presence at the American Society of Hematology (ASH) Annual Meeting 2016 in early December.

Trump Victory Brings V-Shaped Reaction (11-9-16)

 Comments Off on Trump Victory Brings V-Shaped Reaction (11-9-16)
Nov 102016
 
Trump Victory Brings V-Shaped Reaction (11-9-16)

The immediate reaction of a widely unexpected Republican sweep was a huge across the board rally in health care stocks. While it is still very early make definitive conclusions, several positive impacts have resulted in a major reversal of sentiment. Today’s impressive rally (NBI +8%) is a likelihood of some combination of the following macro fundamental and technical changes that are expected to occur with a new, right leaning administration.

Alkermes: Progress in Treating Depression (11-2-2016)

 Comments Off on Alkermes: Progress in Treating Depression (11-2-2016)
Nov 032016
 
Alkermes: Progress in Treating Depression (11-2-2016)

This recommended biotech stock (Alkermes) has delivered the goods with outstanding positive top line data in a treatment for depressions, explains leading biotech analyst John McCamant, editor of The Medical technology Stock Letter.

Catalysts in Biotech (8-19-2016)

 Comments Off on Catalysts in Biotech (8-19-2016)
Aug 222016
 
Catalysts in Biotech (8-19-2016)

John McCamant of BioInvest’s Medical Technology Stock Letter, updates us on the state of the sector, the primary catalysts he see over the rest of the year, and a trio of favorite stocks poised for potentially exciting results.

Pacira: Safer than Opioids? (05-19-2016)

 Comments Off on Pacira: Safer than Opioids? (05-19-2016)
May 202016
 
Pacira: Safer than Opioids? (05-19-2016)

The move away from opiods is gaining momentum, explains biotech sector John McCamant, editor The Medical Technology Stock Letter.

Top Picks 2016: Pharmaceuticals (1-28-2016)

 Comments Off on Top Picks 2016: Pharmaceuticals (1-28-2016)
Jan 292016
 
Top Picks 2016: Pharmaceuticals (1-28-2016)

Jay Silverman, of BioInvest’s Medical Technology Stock Letter, talks with The Money Show about his top pick for 2016-The Medicines Company. #MDCO